Standard BioTools Inc. (LAB)
Statistics
Share Statistics
Standard BioTools has 392.58M shares outstanding. The shares have a market value of 279.67M.
| 392.58M | |
| 8.21% | |
| 0.69% | |
| 76.09% | |
| 210.87M | |
| 31,325 | |
| n/a |
Short Selling Information
Short interest in Standard BioTools is 0.69% of the outstanding shares, representing 2.69M shares. The short ratio is 0.99.
| 2.69M | |
| 0.69% | |
| 1.13% | |
| 0.99 |
Enterprise Valuation
The enterprise value is -168.96M. Enterprise value adds debt and subtracts cash from the company's market cap, providing an alternative valuation for the company.
| -2 | |
| 3.18 | |
| 2.1 | |
| 2.05 |
Financial Position
Standard BioTools's current ratio is 9.1. A current ratio above 1 means that the company has enough short-term assets to cover its short-term liabilities.
| 9.1 | |
| 8.67 | |
| 0.05 | |
| -0.42 | |
| -0.34 | |
| -2775.42 |
Financial Efficiency
Return on Equity is -11.18%, and return on invested capital is -12.7%.
| -11.18% | |
| -6.61% | |
| -12.7% | |
| $219.73K | |
| $220.54K | |
| 385 | |
| 0.13 | |
| 2.45 |
Taxes
| -37.05M | |
| 40.72% |
Stock Price Statistics
The stock price has increased by -44.09% in the past year.
| 1.4 | |
| -44.09% | |
| 0.85 | |
| 1.1 | |
| 41.67 | |
| 3,414,167 |
Income Statement
In the last 12 months, Standard BioTools had revenue of 84.6M and earned 84.91M in profits. Earnings per share was -0.13.
| 84.6M | |
| 42.71M | |
| -62.64M | |
| 84.91M | |
| -66.67M | |
| -72.16M | |
| -0.13 |
Balance Sheet
Standard BioTools has 270.03M in cash on the balance sheet. Total assets are 627.22M, and total liabilities are 28.09M.
| 270.03M | |
| 28.09M | |
| 241.94M | |
| -1.16B | |
| 627.22M | |
| 460.06M |
Cash Flow
Standard BioTools's operating cash flow was -80.3M over the trailing twelve months.
| -80.3M | |
| -2.28M | |
| -82.58M | |
| -0.21 |
Margins
Standard BioTools's gross profit margin was 50.49%, while its operating and net profit margins were -74.04% and 100.37%, respectively.
| 50.49% | |
| -74.04% | |
| -107.55% | |
| 100.37% | |
| -78.81% | |
| -85.3% | |
| -97.61% |
Analyst Forecast
According to 1 stock analysts, the average 12-month price target for Standard BioTools is $1.35. The average analyst rating is "Hold".
| $1.35 | |
| 89.5% | |
| Hold | |
| 1 |
Fair Value
There are several formulas that can be used to estimate the fair value of a stock, including the Graham Number and Lynch Fair Value methods.
| n/a | |
| n/a | |
| n/a | |
| n/a |
Scores
| -0.03 | |
| 4 |